137
Participants
Start Date
August 26, 2022
Primary Completion Date
October 1, 2026
Study Completion Date
December 1, 2026
YH32367
"Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8.~Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll 65 and 40 patients, respectively."
RECRUITING
CHA Bundang Medical Center, Seongnam-si
NOT_YET_RECRUITING
Catholic University of Korea St. Vincent's Hospital, Suwon
NOT_YET_RECRUITING
Ajou University Hospital, Suwon
NOT_YET_RECRUITING
Gachon Gil University Medical Center, Incheon
NOT_YET_RECRUITING
Vanderbilt Ingram Cancer Center, Nashville
NOT_YET_RECRUITING
Ulsan University Hospital, Ulsan
NOT_YET_RECRUITING
Gyeongsang National University Hospital, Jinju
RECRUITING
Dana Farber Cancer Institute, Boston
RECRUITING
Southern Oncology Clinical Research Unit, Adelaide
RECRUITING
Austin Health, Melbourne
WITHDRAWN
Breast Cancer Research Centre - WA, Perth
RECRUITING
Blacktown Hospital, Sydney
RECRUITING
Korea University Anam Hospital, Seoul
RECRUITING
Seoul National University Hospital, Seoul
RECRUITING
Severance Hospital, Yonsei University Health System, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
The Catholic University of Korea, St. Mary's hospital, Seoul
Yuhan Corporation
INDUSTRY